Trial Profile
Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer: A Feasibility Pilot Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2012
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Jun 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
- 25 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2011 New trial record